Share ownership United Therapeutics Corporation

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-12 EST			5-day change	1st Jan Change
493.99 ^USD	+1.12%		+0.96%	+40.00%

12-10	United Therapeutics Insider Sold Shares Worth $3,833,374, According to a Recent SEC Filing	MT
12-09	United Therapeutics Insider Sold Shares Worth $10,050,597, According to a Recent SEC Filing	MT

Share class: United Therapeutics Corporation

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	74,811,109	43,820,714 ( 58.58 %)	30,166,590 ( 40.32 %)	58.58 %

Major shareholders: United Therapeutics Corporation

Name	Equities	%	Valuation
BlackRock Advisors LLC 10.97 %	4,722,094	10.97 %	2 295 M $
Vanguard Fiduciary Trust Co. 10.26 %	4,418,610	10.26 %	2 147 M $
Renaissance Technologies LLC 5.048 %	2,173,392	5.048 %	1 056 M $
Avoro Capital Advisor LLC 4.697 %	2,022,222	4.697 %	983 M $
STATE STREET CORPORATION 4.465 %	1,922,609	4.465 %	934 M $
Wellington Trust Co., NA 3.249 %	1,398,781	3.249 %	680 M $
Geode Capital Management LLC 2.902 %	1,249,660	2.902 %	607 M $
AQR Capital Management LLC 2.291 %	986,478	2.291 %	479 M $
Darwin Global Management Ltd. 1.739 %	748,550	1.739 %	364 M $
LSV Asset Management 1.595 %	686,710	1.595 %	334 M $
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	84.6%
Other	8.02%
State Street Corp.	4.47%
Individuals	1.78%
Swedbank AB	0.76%
Schweizerische Nationalbank	0.29%
Sumitomo Mitsui Trust Group, Inc.	0.22%
Governments	0.18%
Manulife Financial Corp.	0.14%
SEI Investments Co.	0.11%
First Financial Bankshares, Inc.	0.05%
Skandinaviska Enskilda Banken AB	0.04%
Danske Bank A/S	0.04%
MidWestOne Financial Group, Inc.	0.02%
Hancock Whitney Corp.	0.02%
Rathbones Group Plc	0.01%
Cadence Bank	0.01%
The Bank of Nova Scotia	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	81.53%
United Kingdom	6.64%
Individuals	1.78%
Australia	1.72%
Sweden	1.49%
Norway	1.39%
Switzerland	1.21%
Canada	1.1%
France	0.72%
Luxembourg	0.55%
Japan	0.52%
Hong Kong	0.37%
Ireland	0.36%
Germany	0.35%
Netherlands	0.29%
South Korea	0.14%
Denmark	0.13%
Austria	0.1%
Belgium	0.1%
Italy	0.06%
China	0.04%
Singapore	0.04%
United Arab Emirates	0.03%
Cayman Islands	0.02%
Puerto Rico	0.02%
Finland	0.02%
Spain	0.02%
Slovenia	0.01%
South Africa	0.01%
Liechtenstein	0.01%

Based on 1000 largest holdings

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Employees

1,305

Sector

Pharmaceuticals

Calendar

02-24 - Q4 2025 Earnings Release (Projected)

More about the company